Healthcare Edge – ExecEdge

Lunaphore Presents Breakthrough Data on Tumor Microenvironment

Lunaphore Presents Breakthrough Data on Tumor Microenvironment

By Daniella Parra Swiss life sciences company Lunaphore presented data on the capabilities of its COMET platform in the study of the immune status of the tumor microenvironment, the company said in a statement. The research focused on immune checkpoint biomarkers...

Octave Presents Data Supporting Solution for Multiple Sclerosis

Octave Presents Data Supporting Solution for Multiple Sclerosis

By Daniella Parra Octave announced new data at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023, supporting the company’s solution for multiple sclerosis. Researchers assayed 747 patient samples with Octave’s Multiple Sclerosis Disease Activity (MSDA) test, finding eight...

Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel

Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it named Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung brings expertise from her previous roles at SQZ Biotechnologies and her background in intellectual property law, Eterna said...

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license...

Input your search keywords and press Enter.